Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384120387> ?p ?o ?g. }
- W4384120387 endingPage "3061" @default.
- W4384120387 startingPage "3053" @default.
- W4384120387 abstract "To assess the effect of esketamine nasal spray on patient-reported outcomes (PROs) in patients with major depressive disorder having active suicidal ideation with intent (MDSI).Patient-level data from two phase 3 studies (ASPIRE I; ASPIRE II) of esketamine + standard of care (SOC) in patients (aged 18-64 years) with MDSI, were pooled. PROs were evaluated from baseline through end of the double-blind treatment phase (day 25). Outcome assessments included: Beck Hopelessness Scale (BHS), Quality of Life (QoL) in Depression Scale (QLDS), European QoL Group-5-Dimension-5-Level (EQ-5D-5L), and 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9). Changes in BHS and QLDS scores (baseline to day 25) were analyzed using a mixed-effects model for repeated measures (MMRM).Pooled data for esketamine + SOC (n = 226; mean age: 40.5 years, 59.3% females) and placebo + SOC (n = 225; mean age: 39.6 years, 62.2% females) were analyzed. Mean ± SD change from baseline to day 25, esketamine + SOC vs placebo + SOC (least-square mean difference [95% CI] based on MMRM): BHS total score, - 7.4 ± 6.7 vs - 6.8 ± 6.5 [- 1.0 (- 2.23, 0.21)]; QLDS score, - 14.4 ± 11.5 vs - 12.2 ± 10.8 [- 3.1 (- 5.21, - 1.02)]. Relative risk (95% CI) of reporting perceived problems (slight to extreme) in EQ-5D-5L dimensions (day 25) in esketamine + SOC vs placebo + SOC: mobility [0.78 (0.50, 1.20)], self-care [0.83 (0.55, 1.27)], usual activities [0.87 (0.72, 1.05)], pain/discomfort [0.85 (0.69, 1.04)], and anxiety/depression [0.90 (0.80, 1.00)]. Mean ± SD changes from baseline in esketamine + SOC vs placebo + SOC for health status index: 0.23 ± 0.21 vs 0.19 ± 0.22; and for EQ-Visual Analogue Scale: 24.0 ± 27.2 vs 19.3 ± 24.4. At day 25, mean ± SD in domains of TSQM-9 scores in esketamine + SOC vs placebo + SOC were: effectiveness, 67.2 ± 25.3 vs 56.2 ± 26.8; global satisfaction, 69.9 ± 25.2 vs 56.3 ± 27.8; and convenience, 74.0 ± 19.4 vs 75.4 ± 18.7.These PRO data support the patient perspective of the effect associated with esketamine + SOC in improving health-related QoL in patients with MDSI.ClinicalTrials.gov Identifier: ASPIRE I, NCT03039192 (Registration date: February 1, 2017); ASPIRE II, NCT03097133 (Registration date: March 31, 2017)." @default.
- W4384120387 created "2023-07-14" @default.
- W4384120387 creator A5000964073 @default.
- W4384120387 creator A5001543450 @default.
- W4384120387 creator A5018311040 @default.
- W4384120387 creator A5023739443 @default.
- W4384120387 creator A5033188471 @default.
- W4384120387 creator A5047078649 @default.
- W4384120387 creator A5058412566 @default.
- W4384120387 creator A5058521600 @default.
- W4384120387 date "2023-07-13" @default.
- W4384120387 modified "2023-10-17" @default.
- W4384120387 title "Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II)" @default.
- W4384120387 cites W1699842810 @default.
- W4384120387 cites W1970133878 @default.
- W4384120387 cites W1972905657 @default.
- W4384120387 cites W1981511728 @default.
- W4384120387 cites W1990166011 @default.
- W4384120387 cites W1990369310 @default.
- W4384120387 cites W2022886395 @default.
- W4384120387 cites W2026735895 @default.
- W4384120387 cites W2055526664 @default.
- W4384120387 cites W2060791244 @default.
- W4384120387 cites W2094993869 @default.
- W4384120387 cites W2098428600 @default.
- W4384120387 cites W2107213230 @default.
- W4384120387 cites W2108535474 @default.
- W4384120387 cites W2113295845 @default.
- W4384120387 cites W2115910684 @default.
- W4384120387 cites W2119215815 @default.
- W4384120387 cites W2140574319 @default.
- W4384120387 cites W2144317224 @default.
- W4384120387 cites W2152462550 @default.
- W4384120387 cites W2170231382 @default.
- W4384120387 cites W2179463885 @default.
- W4384120387 cites W2470096733 @default.
- W4384120387 cites W2584646667 @default.
- W4384120387 cites W2593714567 @default.
- W4384120387 cites W2606531824 @default.
- W4384120387 cites W2777501810 @default.
- W4384120387 cites W2803306181 @default.
- W4384120387 cites W2923859006 @default.
- W4384120387 cites W2964775597 @default.
- W4384120387 cites W2970674098 @default.
- W4384120387 cites W2992058217 @default.
- W4384120387 cites W3025905746 @default.
- W4384120387 cites W3043831258 @default.
- W4384120387 cites W3082490768 @default.
- W4384120387 cites W3121933124 @default.
- W4384120387 cites W3166865394 @default.
- W4384120387 cites W3187705357 @default.
- W4384120387 cites W3194585947 @default.
- W4384120387 cites W4223504012 @default.
- W4384120387 cites W4285018246 @default.
- W4384120387 cites W4297814361 @default.
- W4384120387 cites W4322700626 @default.
- W4384120387 doi "https://doi.org/10.1007/s11136-023-03451-9" @default.
- W4384120387 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37439961" @default.
- W4384120387 hasPublicationYear "2023" @default.
- W4384120387 type Work @default.
- W4384120387 citedByCount "0" @default.
- W4384120387 crossrefType "journal-article" @default.
- W4384120387 hasAuthorship W4384120387A5000964073 @default.
- W4384120387 hasAuthorship W4384120387A5001543450 @default.
- W4384120387 hasAuthorship W4384120387A5018311040 @default.
- W4384120387 hasAuthorship W4384120387A5023739443 @default.
- W4384120387 hasAuthorship W4384120387A5033188471 @default.
- W4384120387 hasAuthorship W4384120387A5047078649 @default.
- W4384120387 hasAuthorship W4384120387A5058412566 @default.
- W4384120387 hasAuthorship W4384120387A5058521600 @default.
- W4384120387 hasBestOaLocation W43841203871 @default.
- W4384120387 hasConcept C102959455 @default.
- W4384120387 hasConcept C105795698 @default.
- W4384120387 hasConcept C118552586 @default.
- W4384120387 hasConcept C126322002 @default.
- W4384120387 hasConcept C138816342 @default.
- W4384120387 hasConcept C142724271 @default.
- W4384120387 hasConcept C15744967 @default.
- W4384120387 hasConcept C159110408 @default.
- W4384120387 hasConcept C169900460 @default.
- W4384120387 hasConcept C1862650 @default.
- W4384120387 hasConcept C190385971 @default.
- W4384120387 hasConcept C204787440 @default.
- W4384120387 hasConcept C27081682 @default.
- W4384120387 hasConcept C2776641880 @default.
- W4384120387 hasConcept C2778091340 @default.
- W4384120387 hasConcept C2779631380 @default.
- W4384120387 hasConcept C2779951463 @default.
- W4384120387 hasConcept C2780051608 @default.
- W4384120387 hasConcept C3017944768 @default.
- W4384120387 hasConcept C33923547 @default.
- W4384120387 hasConcept C558461103 @default.
- W4384120387 hasConcept C70410870 @default.
- W4384120387 hasConcept C71924100 @default.
- W4384120387 hasConcept C99454951 @default.
- W4384120387 hasConceptScore W4384120387C102959455 @default.
- W4384120387 hasConceptScore W4384120387C105795698 @default.
- W4384120387 hasConceptScore W4384120387C118552586 @default.